CD79A and COVID-19: In contrast, salivary IgA, but not plasma IgA, showed cross‐reactivity across all the variants tested (Alpha, Delta, Beta, Omicron BA.1, Omicron BA.2) (Figure 2i–l; Supplementary figure 4a, b), particularly after the first Vaxzevria dose in COVID‐19 recovered individuals.